Zobrazeno 1 - 10
of 223
pro vyhledávání: '"Hiroki Ishihara"'
Autor:
Nobukiyo Tanaka, Yoshio Furukawa, Takuya Maeda, Hiroki Ishihara, Kazuhiro Dan, Masanori Teramura, Kei Ichihashi, Tetsuro Takase, Yuya Takahashi, Daichi Tsuzura, Akira Shinoda, Masato Fujii, Hisashi Okada, Fumiharu Itabashi, Tomohiko Teramoto
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 1911-1918 (2024)
Abstract Aims Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function. We aimed to determi
Externí odkaz:
https://doaj.org/article/d72ec7a20c7c4c05b175e129bedd9ec1
Autor:
Hiroki Ishihara, Yoshinori Otani, Kazuki Tanaka, Hisao Miyajima, Huy Xuan Ngo, Masashi Fujitani
Publikováno v:
Cell Death and Disease, Vol 14, Iss 9, Pp 1-14 (2023)
Abstract Botulinum toxin-A (BTX) administration into muscle is an established treatment for conditions with excessive muscle contraction. However, botulinum therapy has short-term effectiveness, and high-dose injection of BTX could induce neutralizin
Externí odkaz:
https://doaj.org/article/b3f551c9ba29459189a7cdcd1bb37cc3
Autor:
Yudai Ishiyama, Tsunenori Kondo, Hiroki Ishihara, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe, Toshio Takagi
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 4986-4997 (2021)
Robot-assisted radical cystectomy (RARC) is replacing open radical cystectomy (ORC) and requires clamping of the ureters, resulting in a predisposition to postrenal acute kidney injury (AKI). We investigated the association between ureteral clamping
Externí odkaz:
https://doaj.org/article/e5e68028acb944589fa0183bbf35f60c
Publikováno v:
Materials, Vol 10, Iss 9, p 1085 (2017)
The indirect wavelength selective thermal emitter that we have proposed is constructed using a new microheater, demonstrating the enhancement of the emission peak generated by the surface plasmon polariton. The thermal isolation is improved using a 2
Externí odkaz:
https://doaj.org/article/2dd377c54b874ebdbb040159e8fc0029
Autor:
Yosuke Nakatani, Michiyuki Suzuki, Masaki Tokunaga, Jun Maeda, Miyuki Sakai, Hiroki Ishihara, Takashi Yoshinaga, Osamu Takenaka, Ming-Rong Zhang, Tetsuya Suhara, Makoto Higuchi
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75040 (2013)
Serotonin 1A (5-HT1A) receptors have been mechanistically implicated in micturition control, and there has been a need for an appropriate biomarker surrogating the potency of a provisional drug acting on this receptor system for developing a new ther
Externí odkaz:
https://doaj.org/article/c158a5856b2347dba5decba4be3176a6
Autor:
NANAKA KATSURAYAMA, HIROKI ISHIHARA, RYO ISHIYAMA, YUKI NEMOTO, TAKASHI IKEDA, SHINSUKE MIZOGUCHI, TAKAYUKI NAKAYAMA, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, HIROAKI SHINMURA, YASUNOBU HASHIMOTO, TSUNENORI KONDO, TOSHIO TAKAGI
Publikováno v:
Cancer Diagnosis & Prognosis; Jul/Aug2024, Vol. 4 Issue 4, p496-502, 7p
Autor:
Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
Publikováno v:
Clinical Genitourinary Cancer; Apr2024, Vol. 22 Issue 2, p549-557.e5, 14p
Autor:
Hiroki ISHIHARA, Kazuhide YONEKURA, Masaomi IKEDA, Go INOUE, Masatoshi NAKAJIMA, Yasushi SHIMADA, Keiichi HOSAKA
Publikováno v:
Dental Materials Journal; 2024, Vol. 43 Issue 2, p303-311, 9p
Autor:
Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
Publikováno v:
Targeted Oncology. 18:209-220
Autor:
Hiroki Ishihara, Yudai Ishiyama, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi
Publikováno v:
Clinical Genitourinary Cancer. 21:136-145
To clarify the impact of body mass index (BMI) on treatment outcomes including survival, tumor response, and adverse events (AEs) in patients with advanced renal cell carcinoma (RCC) or urothelial carcinoma (UC) treated with immune checkpoint inhibit